Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fuente, N.
Right arrow Articles by Lopez-Vivanco, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fuente, N.
Right arrow Articles by Lopez-Vivanco, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:537, 2004
© 2004 European Society for Medical Oncology

Tumor lysis syndrome in a multiple myeloma treated with thalidomide

N. Fuente, J. M. Mañe, R. Barcelo, A. Muñoz, T. Perez-Hoyos and G. Lopez-Vivanco*

Department of Medical Oncology, Hospital de Cruces, Plaza de Cruces s/n, Barakaldo 48903, Spain

*E-mail: glvivanco@hcru.osakidetza.net

The first 10% of the full text of this article appears below.

A 60-year-old male with progressive high burden non-secretory multiple myeloma (NSMM) presented with tumor lysis syndrome (TLS) after starting thalidomide. He was diagnosed in 1998 with NSMM stage IIIA according to Durie and Salmon’s classification. Initial treatment consisted of six cycles of vincristine, doxorubicin and dexamethasone (VAD), and double high doses . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?